Author:
Xu Yanan,Zhu Xiaoyin,Wang Hongbo,Sun Shanyue,Yue Xin,Tian Jingwei
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Snyder, G. L. et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology 232, 605–621,
https://doi.org/10.1007/s00213-014-3704-1
(2015).
2. HERBERT Y. MELTZER, SHIGEHIRO, Accepted for publication June 29, MATSUBARA & LEE, a. J.-C. Classification of Typical and Atypical Antipsychotic Drugs on the Basis of Dopamine, D-2 and Serotonin2 pK Values1. The Journal of Pharmacology and Experimental Copyright 0022-3565/89/251-0238(1989).
3. Richard, S. E. et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 64, 633–647 (2007).
4. IAN Creese, D. R. B., Solomon & H. Snyder. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. Science 192, 481–483 (1976).
5. Davis, K. L. K. et al. Dopamine in schizophrenia a review and reconceptualization. The American Journal of Psychiatry 148(11), 1474 (1991).